Share on StockTwits

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Director Vijay B. Samant unloaded 5,000 shares of the stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $8.59, for a total transaction of $42,950.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded down 0.11% on Wednesday, hitting $8.94. 597,743 shares of the company’s stock traded hands. Raptor Pharmaceutical Corp. has a 52 week low of $5.40 and a 52 week high of $17.72. The stock has a 50-day moving average of $12.88 and a 200-day moving average of $13.85. The company’s market cap is $558.6 million.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.18) by $0.01. The company had revenue of $10.20 million for the quarter. On average, analysts predict that Raptor Pharmaceutical Corp. will post $-0.58 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on RPTP shares. Analysts at Ladenburg Thalmann downgraded shares of Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating in a research note on Friday, February 21st. They now have a $15.50 price target on the stock. Separately, analysts at Wedbush downgraded shares of Raptor Pharmaceutical Corp. from a “neutral” rating to an “underperform” rating in a research note on Wednesday, February 5th. Finally, analysts at Leerink Swann raised their price target on shares of Raptor Pharmaceutical Corp. from $17.00 to $19.00 in a research note on Thursday, January 23rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $16.58.

Raptor Pharmaceuticals Corp. (NASDAQ:RPTP), formerly TorreyPines Therapeutics, Inc, is an early development-stage Company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.